Interim study results show brentuximab vedotin has potential in non-Hodgkin lymphoma patients

摘要

The results of an ongoing, open-label Phase II study, presented at the American Society of Hematology Annual Meeting held in December 2013, has demonstrated that "compelling antitumor activity has been observed with brentuximab vedotin," in the "interim analysis of 62 patients with highly refractory B-cell lymphomas."This study is evaluating the antitumor activity of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL) with the inclusion of B-cell neoplasms.